Terminated PHASE2 INTERVENTIONAL 3-arm NCT02954991

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Mirati Therapeutics Inc.

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Glesatinib Mocetinostat Nivolumab Sitravatinib

Updated 20 times since 2017 Last updated: Apr 10, 2024 Started: Nov 7, 2016 Primary completion: Nov 4, 2021 Completion: Nov 4, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated as a result of Sponsor portfolio reprioritization.

Other terminated trials from Mirati Therapeutics Inc.

More terminations from Mirati Therapeutics Inc.

Other Carcinoma, Non-Small-Cell Lung trials with similar outcome

Browse all Carcinoma, Non-Small-Cell Lung trials

This PHASE2 trial investigates Carcinoma, Non-Small-Cell Lung and is currently terminated or withdrawn. Mirati Therapeutics Inc. leads this study, which shows 20 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
May 2024 — Jul 2024 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Dec 2022 — May 2024 [monthly]

Completed PHASE2
May 2022 — Dec 2022 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

Sep 2021 — May 2022 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Jul 2019 — Mar 2020 [monthly]

Recruiting PHASE2
Apr 2019 — Jul 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Feb 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE2
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE2
Apr 2017 — Jun 2017 [monthly]

Recruiting PHASE2
Feb 2017 — Apr 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mirati Therapeutics Inc.

Data source: Mirati Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Beverly Hills, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Denison, United States , Denver, United States , Detroit, United States , Duarte, United States , Fairfax, United States and 14 more locations